Antiangiogenic factors are potent endothelial cell growth inhibitors that have been shown to inhibit angiogenesis in vitro and tumor growth in mice. We have demonstrated the synergistic antitumor effect of antiangiogenic genes (mouse angiostatin: pBLASTmAngio; and mouse endostatin: p-BLAST42-mEndo XV) delivered to tumors by low-voltage electroporation in mouse colon 26 models. A synergistic antitumor effect was strongly suggested by in vivo tumor growth kinetics, as well as in survival studies with the mice. RT-PCR confirmed that the fragments of each gene were transferred by low-voltage electroporation in the tumor. Decreased microvessel density measurements in tumors also confirmed the efficacy of the synergistic antitumor effect of both genes. Significant growth inhibition was observed in mice treated with a 1:1 proportion of angiostatin and endostatin genes, and the order of the both genes transferred (first the endostatin gene, followed 1 week later by the angiostatin gene) had a profound inhibitory effect on tumor growth. These data suggest that in vivo delivery of antiangiogenic genes with low-voltage electroporation could be a possible therapeutic strategy for established solid tumors when both genes were applied in combination.
A ntiangiogenic approaches to cancer treatment represent a promising new strategy. Antiangiogenic recombinant proteins such as angiostatin and endostatin, which are the internal antiangiogenic factors, prevent the formation of new vessels within the growing tumor, leading to its growth arrest and, in some cases, to its regression. [1] [2] [3] However, long-term systemic delivery of these proteins poses a number of difficult logistic and pharmacological problems in preclinical models due to the stability and solubility of these agents. 4, 5 In order to facilitate the delivery of such recombinant proteins, transfer of their genes into neoplastic tissues in vivo using a variety of viral and nonviral carriers has been proposed, and several gene therapy studies have demonstrated tumor shrinkage. [6] [7] [8] [9] [10] [11] Electroporation-mediated gene transfer relies upon direct delivery of plasmids into cells permeabilized by electric fields, stimulating increased cell permeability by a variety of genes entering the cell through the membrane micropores. This method is more efficient than transfer using nonviral vectors. [12] [13] [14] Although there have been several reports of electroporation used in vivo to transfer therapeutic genes, 15, 16 usually by applying high-voltage direct current electric pulses to cells in vitro or tissues in vivo, a lower level of electric power is desirable in a clinical setting. 17 In recent study, we showed that low-voltage electroporation combined with chemotherapy has been effective against antitumor growth and also convenient in clinical use. 18 To our knowledge, there have been no reports that antiangiogenic genes have been delivered successfully using the low-voltage electroporation to inhibit tumor growth.
In this study, we examined whether low-voltage electroporation-mediated concurrent gene transfer of angiostatin and endostatin genes inhibited angiogenesis and the growth of colon 26 tumors implanted in mice.
Materials and methods

Plasmid DNA
The plasmid constructs used were: pRL-TK encoding the luciferase gene under the control of the HSV-TK promoter (Toyo Inki, Japan); pcDNA3 encoding the LacZ gene under the control of the CMV promoter (Invitrogen, Japan); mouse angiostatin expression plasmid, pBLAST-mAngio (5.47 kb) (Invivogen, San Diego, USA); and mouse endostatin expression plasmid pBLAST42-mEndoXV (3.64 kb) (Invivogen, San Diego, USA). Plasmid DNA was isolated and purified from contaminating endotoxin using EndoFree Plasmid Mega Kit (Qiagen).
Cell line and culture method
Colon 26, a carcinogen-induced, undifferentiated colon adenocarcinoma cell line, was kindly provided by Dr J Hamuro (Basic Research Laboratories, Ajinomoto, Tokyo, Japan). This cell line was cultured in RPMI 1640 medium supplemented with 4 mM L-glutamine (Gibco, Japan) and 5% fetal bovine serum, and was maintained in a humidified atmosphere that contained 5% CO 2 . The cells used in this study were more than 95% viable, as tested with the trypan blue exclusion dye method.
Intratumoral DNA injection and electroporation
Female Balb/c mice, 7-8 weeks old, were purchased from Shizuoka Laboratory Animal Center (Hamamatsu, Japan). Animals were housed and cared for according to the animal care guidelines of the Graduate School of Medicine, Chiba University. All methods in this study were approved by the ethical committee of Chiba University Animal Care. Procedures were conducted with animals placed under general anesthesia by diethyl ether. Colon 26 tumor cells (1 Â 10 6 ) were suspended in 0.5 ml of RPMI 1640 and inoculated subcutaneously (s.c.) into the mice. Tumors were allowed to grow for 7 days up to about 8-9 mm in diameter.
Mice were anesthetized with satisfactory diethyl ether. At 5 min after the intratumor (i.t.) injection of plasmid DNA in 100 ml of PBS (standard PBS without Ca 2 þ and Mg 2 þ ), using a 1 ml syringe with a 27-gauge needle, electric pulses were delivered percutaneously via two parallel stainless-steel electrodes by inserting them to an appropriate depth (3-5 mm) into the tissue immediately surrounding the tumor, so that the neoplasm was contained within the volume delineated by the needles. According to our previous report with regard to electrochemotherapy in colon 26 tumors, we established eight electric pulses (5 time/s) of 100 ms duration as the electroporation standard using a square electroporator CUY 21 (TR TECH Co Ltd, Tokyo, Japan). 18 The shape of the pulse was a square wave. The nominal applied field strengths (voltage to electrode spacing ratio) of the pulses were experimental variables that ranged from 25 to 100 V/ cm. Electrodes consisted of a pair of tungsten needles 10 mm in length and 0.4 mm in diameter.
Luciferase activity
Luciferase activity of the tissue was measured by the following methods: 19 mice were killed 3 days after transferring pRL-TK encoding luciferase gene by electroporation under various conditions; the excised tumor material was minced and placed in 1 ml of renilla luciferase assay lysis buffer (Promega, Madison, WI); and the tissue was dissociated until it was completely dissolved. A measure of 25 ml of each sample were added to 100 ml substrate, and assayed for luciferase activity, using a luminometer (Lumat LB 9507; EG and G Berthhold, Tokyo, Japan). Total protein content for each sample was determined by the Bradford method, using bovine serum albumin (BSA) as a standard, and absorbencies were read at 595 nm on a UV visible recording spectrophotometer (Microplate reader, model 550; Bio-Rad, Tokyo, Japan). Results were normalized to yield luciferase activity in RLU/mg BSA protein.
RT-PCR of angiogenesis inhibitor (angiostatin and endostatin)
Total RNA was extracted from tumors with an RNeasy Mini Kit (Qiagen) at 3 days after transferring angiogenesis inhibitor genes by electroporation. cDNA was synthesized from total RNA with a first-strand cDNA Synthesis kit for RT-PCR (Roche, Mannheim, Germany). Using the cDNA as a template, angiostatin and endostatin were amplified with the following primers: angiostatin -forward 5
Post-treatment monitoring
Post-treatment monitoring was performed as follows: the tumor volumes were calculated by measuring the diameters along the two largest dimensions with a caliper every 3-4 days and using the formula V ¼ a Â b 2 T/6, where V is the volume, a the large diameter and b the small diameter. 18 
Immunohistochemistry of CD31
After 2 weeks of electroporation, microvessel density (MVD) studies were performed. 20 Tumor microvessels were stained using a mouse monoclonal antibody to the CD31 antigen on endothelial cells (BD Biosciences Pharmingen, USA). Frozen sections (5 mm) were cut on a cryostat, air-dried, and fixed in acetone at 41C for 10 minutes. The sections were treated with 100% ethanol and then 0.3% H 2 O 2 solution at room temperature for 30 minutes to block endogenous peroxidase activity (background). The primary antibody was applied diluted 1:100 for 30 minutes at room temperature by standard washing. A biotinylated secondary antibody (Dako, Tokyo, Japan) was then applied for 30 minutes at room temperature, followed by standard washing. A peroxidase-conjugated streptavidin (Dako, Tokyo, Japan) was applied for 30 minutes at room temperature and 3,3 0 -diaminobenzidine substrate solution (Dako, Tokyo, Japan) was prepared for 5 minutes at room temperature or until the desired color intensity was achieved. Slides were stained in hematoxylin solution for 60 seconds and rinsed thoroughly in water. They were then dehydrated with alcohol, cleared in xylene, and placed in coverslips. MVD was scored as an average of five random fields ( Â 200).
Statstical analysis
The statistical P-value was determined by means of the unpaired t-test, comparing the data on average luciferase activity, tumor volume, and MVD in each experimental series. The Kaplan-Meier method and the log-rank test were used to analyze post-treatment survival of the mice. A P-value of less than .05 was considered to be statistically significant.
Results
Optimal conditions of electroporation for colon 26 in vivo luciferase activity
The optimal voltage (V) level of the electric pulses was determined when other conditions were fixed as follows: with eight electric pulses, 100 ms in duration, 50 mg of pRL-TK was injected into each tumor nodule. The results indicate an increase in the mean luciferase activity with an increase in voltage up to 50 V (Fig 1a) . Colon 26 that was subjected to 25 V expressed a mean luciferase activity level of 33.2720.2 RLU/mg of BSA, which increased to 62.2751.2 RLU/mg of BSA in colon 26 that was subjected to 50 V (P ¼ 0.0456; mean7SD). However, the mean luciferase activity in colon 26 that was subjected to 75 and 100 V decreased to 57.573.9 RLU/mg of BSA and 51.4729.7 RLU/mg of BSA, respectively. No statistical difference was found in the levels of luciferase activity with voltage levels higher than 50 V. No detectable levels of luciferase activity were observed in s.c. colon 26 when the plasmid was directly injected.
The optimal concentration of plasmid DNA for injection into tumor nodules was determined when other conditions were fixed as follows: eight electric pulses, 100 ms in duration, 50 V of electroporation (Fig 1b) . Colon 26 that was injected with 25 mg of plasmid DNA expressed a mean luciferase activity level of 13.9713.4 RLU/mg of BSA, which increased to 62.2751.2 RLU/mg of BSA in colon 26 that was injected with 50 mg of plasmid DNA (P ¼ .0497; mean7SD). No statistical difference as to the level of luciferase activities was observed among the plasmid DNA injection groups receiving more than 50 mg. Each experimental group consisted of seven mice.
According to these results, the optimal condition for electroporation gene transfer in the experiments were given as follows: 50 V, 100 ms in duration, eight pulses, and 50 mg of plasmid DNA injection.
Time course of luciferase activities
The time course of luciferase activities by electroporation in vivo was determined after electroporation at 50 V. The luciferase activity peaked 3 days after electroporation and gradually decreased to approximately 4.3% of the maximum value by 1 week after electroporation (Fig 2) .
RT-PCR of angiogenesis inhibitor (angiostatin and endostatin)
As shown in Figure 3 , expression of angiostatin or endostatin gene was determined by RT-PCR using primers directed against angiostatin or endostatin, respectively. An 803-bp fragment (angiostatin) or a 181-bp fragment (endostatin) was observed in the RT-PCR product from DNA of tumors to which angiostatin or endostatin genes had been transferred by electroporation but not in the product from the DNA of cells with luciferase genes. The tumors transferred from both genes in combination showed double fragments.
MVD measurement in tumors
To determine the effect of angiostatin and endostatin on vascular growth in vivo, MVD was measured in frozen sections of tumors by utilizing anti-CD31. The MVD in (Fig 4) .
Effect of angiogenesis inhibitor genes on tumor growth and survival
Electroporation-mediated gene transfer was performed with an angiostatin or endostatin gene, 50 mg/0.1 ml in PBS i.t., and the application of a 50 V electric field. The results in terms of the tumor growth are shown in Figure 5a . The angiostatin group had depressed tumor growth, but there was no significant difference between the angiostatin group and luciferase group (P ¼ .7978).
There was a significant difference in tumor growth between the endostatin group and luciferase group (P ¼ .03). However, growth was reduced most in tumors to which both angiostatin and endostatin genes were transferred in combination (Po.0001). Figure 5b shows survival differences among the groups, as well as the synergistic effect on survival in the group to which angiostatin and endostatin genes had been transferred in combination (P ¼ .003). No significant differences were observed among angiostatin, endostatin, and control groups as to the number of survival days.
Electrogene therapy was carried out with several different proportions of both antiangiogenic genes (Fig 6a) . The total amount of plasmid DNA transferred simultaneously by electroporation was 50 mg. Most inhibition of tumor growth was observed in the group of mice treated with both genes in a 1:1 proportion. There was no significant difference in tumor growth between groups of mice treated with both genes in 1:3 or 3:1 proportions. There was a significant difference in tumor growth between the 1:1 proportion group and the luciferase group (P ¼ .0073). No significant difference in tumor growth was observed between groups of mice treated with both genes in 1:3 or 3:1 proportions.
The effect on tumor growth of the order in which the two genes were administered is shown in the Figure 6b . The group in which the angiostatin gene (25 mg) was transferred first by electroporation, followed by the endostatin gene (25 mg) 1 week later, showed no inhibition of tumor growth; however, the group, in which the endostatin gene (25 mg) was transferred first, followed by angiostatin gene (25 mg), showed significant inhibition of tumor growth (P ¼ .0022). The growth inhibition observed was the same as in the group of mice in which both genes were simultaneously transferred. 
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Discussion
The present results suggest that plasmid DNA containing mouse angiostatin, and mouse endostatin genes transferred in combination (rather than either gene alone), with low-voltage electroporation into s.c. inoculated colon 26 tumors in syngeneic Balb/c mice displayed significant inhibition of tumor growth. A synergistic antitumor effect was strongly observed in vivo tumor growth kinetics as well as in survival studies with regard to these mice. Significant growth inhibition was observed in mice treated with a 1:1 proportion of transferred angiostatin and endostatin genes, but not in mice treated with a 1:3 or 3:1 proportion. When the endostatin gene was transferred first, followed by the angiostatin gene, there was profound inhibition of tumor growth; however, when the order was reversed, these results were not obtained.
RT-PCR confirmed that fragments of each gene were transferred into the tumor by low-voltage electroporation. Decreased MVD in tumors also confirmed the efficacy of the synergistic antitumor effect of the two genes. We used low-voltage electroporation to transfer genes encoding endostatin and angiostatin and confirmed the expression of their mRNAs by RT-PCR. Electroporation facilitates transfer of chemicals or plasmid DNA from extracellular milieu into cells by increasing the permeability of the cell membrane. 13, 14 This method of The effect on tumor growth of the order in which the two genes were administered is shown. The group in which the angiostatin gene was transferred followed by the endostatin gene (1 week later) showed no inhibition on the tumor growth. However, the group in which the endostatin gene was transferred first, followed by the angiostatin gene, showed significant inhibition on the tumor growth (P ¼ .0445). EP: electroporation.
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transferring foreign genes is simple, and plasmid DNA may be transferred repeatedly into any type of tissue. The efficiency of transfer, although lower than with viral vectors, is nonetheless higher than that offered by nonviral lipoplexes. 12 Electroporation is usually performed by applying high-voltage direct current electric pulses (1000-2000 V/cm) to cells in vitro or tissues in vivo. 15, 16 At low voltages, the plasma membranes of cultured cells are not sufficiently altered to allow the passage of molecules, whereas at high voltages, the cells are irreversibly damaged. It has been reported that the efficacy of transferring of molecules into cells is roughly proportional to the amount of heat that is generated when electric square pulses are applied to a field, unless the tissues or cells are irreversibly damaged. Accordingly, electroporation at 1000 V/cm for 100 milliseconds is equivalent to electroporation at 25 V/cm for 160 milliseconds. 12 In addition, efficacy is also dependent on the concentration gradient of the molecules that are to be delivered. 21 The longer the loading period, the longer the cell surface is open. Hence, it is likely that more of the agent would be transferred from the extracellular to the intracellular space. In our experiments, low-voltage in vivo electroporation was applied, but to achieve the same quantity of heat, longer loading periods can be employed. Cichon et al 22 reported that the electrotransfer of the gene encoding endostatin into neoplastic mouse tissue resulted in the inhibition of primary tumor growth and metastatic spread. They reported that there was no improvement in the efficiency of gene transfers into tumors beyond a threshold voltage, and that distinct tissue damage could be seen at higher voltages, especially with combinations of high voltage and lengthy impulse time. The best combination for electrotransfer would be a low voltage for a short time, which would minimize tissue damage. However, they used one impulse of 200 V, which was much higher than the voltage we used, for 100 milliseconds.
Synergy between angiostatin and endostatin was suggested by a recent report that showed potent antitumor activity of the combination in an ovarian cancer model in nude mice. 23 A synergistic antitumor effect of the antiangiogenic genes (angiostatin and endostatin) in vitro and in vivo, mediated by transfer of both genes in combination was reported in melanoma and murine leukemia models, 24 in which both genes were delivered to tumor cells by retroviral gene transfer. There was a synergistic benefit for the combination group in having smaller tumors than either the angiostatin-or the endostatin-alone group and this was statistically significant. In our experiments, a synergistic antitumor effect was observed when both genes were transferred simultaneously by low-voltage electroporation into tumor nodules in a 1:1 proportion. The two antiangiogenic agents in combination may act on separate pathways during induction of their synergistic antiangiogenic effect. Angiostatin and endostatin induce apoptosis. [25] [26] [27] It is possible that induction by means of this process may be more potent than with either angiostatin or endostatin alone. It may also be due to the different downstream effectors of both the agents. Reduction of Bcl-2 and Bcl-XL has been observed with endostatin-mediated apoptosis. 27 Cell cycle regulatory proteins that are critical to endothelial cell proliferation such as M-phase phosphoproteins have recently been shown to be downregulated by angiosatin. 28 Furthermore, an angiostatin-endostatin fusion gene showed significantly greater inhibition of human umbilical vein endothelial cell tube formation in vitro and potent antitumor effects in a melanoma model in vivo, than angiostatin, endostatin, or a combination of the two genes. 20 In our experiments, transfection with angiostatin gene first and endostatin gene later was inefficient, whereas reverse order induced a significant antitumor effect. In the group, in which angiostatin was transferred first, followed by endostatin 1 week later, the tumor volume at the introduction of endostatin was 468.37189.0 mm 3 (n ¼ 6). However, in the group of the reverse order, in which endostatin was applied first, the tumor volume at the introduction of angiostatin (1 week later than endostatin) was 377.3790.0 mm 3 (n ¼ 6). Significant difference was observed in the volume between those two groups (Po.001). Our data, as well as others, 24 indicate that endostatin has more potent antitumor effect than angiostatin. Therefore, when endostatin gene was applied first, tumors were probably smaller and endostatin might be able to show complementary antitumor effect when angiostatin was applied 1 week later.
The synergistic effect of both genes was also confirmed by MVD measurement of tumors. Tumor growth inhibition was observed when the endostatin gene was transferred into the nodule first, followed by the angiostatin gene (1 week later). Transfer in the reverse did not show any antitumor effect. So far, we cannot provide an adequate explanation for this phenomenon. Although further studies are required in order to clarify the synergistic mechanism of angiostatin and endostatin gene transfer by low-voltage electroporation, such studies are likely to supply further evidence that gene therapy using both antiangiogenic genes in combination is useful for its antitumor effect.
In this series of experiments, pBLAST42-mEndoXV was used as a mouse endostatin gene. Endostatin is a fragment of the C-terminal domain NC1 of collagen XVIII that inhibits angiogenesis and tumor growth. Collagen XV contains an endostatin-like region with 61% sequence identity with that of collagen XVIII. 29 It has been reported that both endostatin/NC1-XV and endostatin/NC1-XVIIIB inhibit chick chorioallantoic membrane angiogenesis in a distinct manner, which is dependent on the cytokine used for stimulation. 29 Both endostatin isoforms share a compact globular fold, but differ in certain binding properties with respect to other proteins and cells, as well as in tissue distribution, indicating that their repertoire of biological interactions is overlapping but not identical. Endostatin causes neovascularization depression by downregulation of vascular endothelial growth factor expression in tumor cells and causes direct DNA damage. XV collagen also has the same function.
In conclusion, low-voltage electroporation-mediated combined transfer of antiangiogenic factor genes into solid tumors may produce antitumor effects. However, further investigation is required in order to clarify the mechanism of the synergistic antitumor effect of angiostatin and endostatin genes on tumor growth; the results suggest that low-voltage electroporation could be a possible therapeutic strategy for established solid tumors if antiangiogenic factor genes are applied in combination.
